[ad_1]
Dr. Tom butera, President and CEO of Volition Veterinary Diagnostics Development, LLC said, “be able to use the Nu.Q® Testing not only to screen for cancer and help identify disease earlier, but also to monitor disease progression as an early indication that a dog is coming out of remission, will meet a real unmet need in the market. We expect this disease surveillance product to be our second Nu.Q® Veterinary product. We believe this product has significant potential to help improve treatment and quality of life for dogs, while providing additional valuable information to inform the clinical decision-making process for the veterinarian and animal owner. While the veterinary business team has been busy negotiating global licensing and distribution agreements, I would like to salute the hard work and joint research efforts of the Texas A&M University and the Volition team; we are delighted to present these two studies at the world’s largest conference in veterinary oncology. “
“The data shows that Nu.Q® The veterinarian may serve as a more sensitive measure of both minimal residual disease and remission and could be a useful surveillance test for dogs with cancer. Given Nu.Q® is a simple blood test, it would be incredibly useful in the clinic and in the general veterinarian’s office, â€said Dr. Heather Wilson-Robles, teacher at Texas A&M University, Medical Director of Volition Veterinary Diagnostics Development LLC and President of VCS.
Dr Robles added: “The second poster reports our first study using Nu.Q® Capture, Volition’s enrichment tool, to better understand circulating nucleosome types and their genomic patterns in the plasma of dogs with lymphoma. It was exciting to see that once again, animal data show results similar to human studies in that patients with canine lymphoma have circulating nucleosomes lacking in binding DNA (i.e. say shorter nucleosomes) which are not detected in the plasma of healthy dogs and that Nu.Q® Capture is able to enrich the nucleosomes associated with canine cancer in the plasma of patients with lymphoma. We look forward to expanding our research in this area. ”
An interview with Dr. Heather Wilson-Robles, medical director of Volition Veterinary Diagnostics Development LLC.
The summaries
Assessment of plasma nucleosome concentrations as a tool for the treatment and monitoring of disease in dogs with cancer.
Wilson Robles, H[1], Miller, T[1], Miller, P[1], Jarvis, J[1], Butera, T[2], Matsushita, M[1], Terrell, J[2], Kelly, TK[2]
Texas A&M University College of Veterinary Medicine and Biomedical Sciences[1]; Volition America and Volition Veterinary Diagnostics[2]
To see the summary presentation, click on HERE or download the poster, click HERE
Enrichment tools to better understand the types of circulating nucleosomes and their genomic patterns in the plasma of dogs with lymphoma.
Bourne, K[1], Miller, T[1], Jarvis, J[1], Butera, T[2], Kelly, TK[2], Davis, B[1], Wilson-Robles, H[1]
Texas A&M University College of Veterinary Medicine and Biomedical Sciences[1]; Volition America and Volition Veterinary Diagnostics[2]
To see the summary presentation, click on HERE or download the poster, click HERE
To learn more about Volition Veterinary and Nu.Q® Veterinarian, please visit our webpage at https://volition.com/veterinary
About Volition
Volition is a multinational epigenetics company that applies its Nucleosomics â„¢ platform across its subsidiaries to develop simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-changing diseases, including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also improve their quality of life. The tests are based on the science of Nucleosome â„¢, which is the practice of identifying and measuring nucleosomes in the bloodstream or other body fluids – an indication that disease is present. Volition mainly focuses on human diagnostics and surveillance, but also has a subsidiary focused on animal diagnostics and surveillance.
Volition’s research and development activities focus on Belgium, with a small laboratory at California and additional offices at Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease surveillance products to market.
For more information on Volition, visit the Volition website volition.com or contact us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
Youtube: https://www.youtube.com/user/VolitionRx
Content found at Volition’s website, Twitter, LinkedIn, Facebook and YouTube is not incorporated by reference in this document and should not be considered part of this document. Volition, Twitter, LinkedIn, Facebook and YouTube website addresses are included in this document as inactive text references only.
Media / investor contacts
Safe Harbor Declaration
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which relate to matters involving risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in forward-looking statements. Words such as “expect”, “anticipate”, “intend”, “plan”, “aim”, “targets”, “believe”, “research”, “estimate”, “optimize” , “Potential”, “objective,” “suggests”, “could”, “would”, “should”, “could”, “will” and similar expressions identify forward-looking statements. These forward-looking statements concern the effectiveness of testing blood tests for diagnosis, prognosis and monitoring of Volition’s diseases, the ability of Volition to develop and successfully commercialize such test platforms for the early detection of cancer and other diseases as well as to serve as a diagnostic, prognosis or disease surveillance tools for these diseases and the timing of product launches and publications. Volition’s actual results may differ materially from those shown in these forward-looking statements due to numerous risks and uncertainties, including, without s ” to limit results of studies testing the effectiveness of its tests. For example, if Volition is unable to develop and market products for diagnosis, prognosis or disease surveillance, it may not be able to execute its plan of operations. Other risks and uncertainties include the failure of Volition to obtain the necessary regulatory authorizations or approvals to distribute and market future products; a market failure to accept products from Volition’s development pipeline or any other disease diagnostic, prognostic or surveillance product that Volition may develop; the failure of Volition to ensure adequate protection of intellectual property; Volition will face fierce competition and the products planned by Volition may become obsolete due to the highly competitive nature of the disease diagnostics and surveillance market and its rapid technological change; slowdowns in domestic and foreign economies; and other risks identified in Volition’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as in other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections regarding the business of Volition based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release and, except as required by law, Volition does not undertake to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics ™ and Nu.Q® and their respective logos are trademarks and / or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names mentioned in this press release are the property of their respective owners.
SOURCE VolitionRx Limited
[ad_2]
